Keytruda Approvals: A Timeline

Source: BioSpace, September 2019

One month after Merck touted the strength of Keytruda as a tent-pole medication, the checkpoint inhibitor earned approval for its 22nd indication from the U.S. Food and Drug Administration.

Six years after it was first launched, Keytruda has become one of the best-selling drugs in the world. Last year, it generated more than $7 billion in revenue for Merck and that is only predicted to grow, particularly as the drug wins approval for new indications. During an Investor’s Day conference in June, Merck Chief Commercial Officer Frank Clyburn said in a short time, Keytruda has become a foundational cancer treatment.


Read the original full article